Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma - Summary - MDSpire

Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

  • By

  • Yetian Dong

  • Tingting Yang

  • Mengyu Zhao

  • Fengmei Song

  • Rongrong Chen

  • Mingming Zhang

  • Ruimin Hong

  • Jingjing Feng

  • Shan Fu

  • Pingnan Xiao

  • Huijun Xu

  • Jiazhen Cui

  • Simao Huang

  • Guoqing Wei

  • Alex H. Chang

  • He Huang

  • Yongxian Hu

  • August 20, 2025

  • 0 min

Share

Objective:

To evaluate the toxicity and efficacy of autologous humanized CAR-T cell therapy (hCART19) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL), highlighting its potential impact on treatment outcomes.

Key Findings:
  • The study included 26 patients with a median follow-up of 20.3 months.
  • Safety evaluations indicated manageable levels of CRS and ICANS.
  • Efficacy results showed a significant objective response rate and improved survival metrics.
Interpretation:

The findings suggest that hCART19 therapy is both safe and effective for patients with R/R B-NHL, with promising outcomes in terms of response and survival.

Limitations:
  • Small sample size limits generalizability; further studies are needed to confirm findings.
  • Short follow-up duration may not capture long-term outcomes, necessitating extended monitoring.
  • Exclusion of patients previously treated with CAR-T cells may affect applicability, suggesting a need for broader inclusion criteria in future studies.
Conclusion:

Autologous humanized CD19 CAR-T cell therapy demonstrates a favorable safety profile and efficacy in treating relapsed/refractory B-NHL, warranting further investigation to validate these promising outcomes.

Original Source(s)

Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

  • by Yetian Dong, Tingting Yang, Mengyu Zhao, Fengmei Song, Rongrong Chen, Mingming Zhang, Ruimin Hong, Jingjing Feng, Shan Fu, Pingnan Xiao, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Chang, He Huang, Yongxian Hu

  • August 20, 2025

Related Content

Anatomy-aware lymphoma lesion detection in whole-body PET/CT

Rapidly Expanded EBV-Specific T Cells for the Treatment of Refractory EBV Reactivation and EBV-Related Lymphoproliferative Disorders

The First NCI-Designated Comprehensive Cancer Center Using 3D Genomics Testing to Diagnose Lymphoma and Sarcoma—a True Game Changer

Diagnosing lymphoma and sarcoma can be extraordinarily complex, with more than 70 recognized subtypes of lymphoma and more than 100 distinct types of sarcoma. Many subtypes share similar features yet behave in dramatically different ways in standard testing, leaving oncologists with diagnostic quandaries and delays to treatment.

  • by

  • February 24, 2026

  • 4 min